A phase 1/2 clinical trial of LP-184 for the treatment of atypical teratoid rhabdoid tumor (ATRT)
Latest Information Update: 24 Feb 2022
At a glance
- Drugs Irofulven (Primary)
- Indications Rhabdoid tumour
- Focus Adverse reactions
- 24 Feb 2022 New trial record
- 15 Feb 2022 According to a Lantern Pharma media release, this trial is expected to begin in late 2022.